At a glance
ClinicalIndex Comparison RecordN/ACompleted· 135 enrolled
Drug / intervention
Rituximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)
In Brief
An observational study evaluating Rituximab for Rheumatoid Arthritis. Completed, enrolled 135 participants across 14 sites.
Detailed Summary
This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate response to one or more tumour necrosis factor inhibitor (anti-TNF) therapies.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedJun 2012
Primary CompletionSep 2015
TodayJul 2026
First PostedJun 6, 2012
Enrollment StartFeb 1, 2012
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.1 years ago
Interventions
Rituximabbiological
Rituximab administered according to prescribing information and normal clinical practice.